title: Clinical pharmacokinetics during continuous haemofiltration.
abstract: Continuous haemofiltration is an extracorporeal technique that is increasingly used to remove fluid, electrolytes, and other waste products from the blood supply of critically ill patients with acute renal failure. Continuous arteriovenous haemofiltration (CAVH), where the blood exits the body from an artery and re-enters through a vein, is widely used. Continuous venovenous haemofiltration (CVVH), where blood both exits and enters through a vein by way of a mechanical pump, avoids problems that result from the variable ultrafiltration rate found during CAVH. Continuous arteriovenous or venovenous haemodiafiltration (CAVHD or CVVHD) combine continuous haemofiltration and haemodialysis. All methods involve ultrafiltration of the patient's blood through a filter that is highly permeable to water and small molecules. Drug elimination by haemofiltration depends mainly on the rate of ultrafiltration, the drug protein binding and the sieving coefficient of the membrane. Because patients undergoing continuous haemofiltration have impaired renal function, dosage reduction is often recommended so that adverse drug reactions are avoided. In contrast, if drug removal by haemofiltration is significant, dosage supplementation may be required to ensure therapeutic efficacy of the drug. Therefore, knowledge of the impact of continuous haemofiltration on drug elimination and the pharmacokinetic profile of drugs is essential to good clinical management. The currently available information on the clinical pharmacokinetic aspects of drug therapy during continuous haemofiltration are summarised. Drugs commonly associated with haemofiltration therapy are tabulated with updated pharmacokinetics and drug-monitoring information.
authors.affiliation: Laboratoire de Pharmacocinétique, Faculté de Pharmacie, Montpellier, France.
authors.forename: F
authors.initials: F
authors.lastname: Bressolle
authors.forename: J M
authors.initials: JM
authors.lastname: Kinowski
authors.forename: J E
authors.initials: JE
authors.lastname: de la Coussaye
authors.forename: N
authors.initials: N
authors.lastname: Wynn
authors.forename: J J
authors.initials: JJ
authors.lastname: Eledjam
authors.forename: M
authors.initials: M
authors.lastname: Galtier
mesh_terms: D000617:Aminoglycosides; D000900:Anti-Bacterial Agents / Q000493:pharmacokinetics; D002511:Cephalosporins / Q000493:pharmacokinetics; D015377:Cilastatin / Q000493:pharmacokinetics; D000077728:Cilastatin, Imipenem Drug Combination; D004338:Drug Combinations; D006207:Half-Life; D006440:Hemofiltration; D006801:Humans; D015378:Imipenem / Q000493:pharmacokinetics; D008657:Metabolic Clearance Rate; D010599:Pharmacokinetics; D011485:Protein Binding; D014018:Tissue Distribution; D014462:Ultrafiltration; D014640:Vancomycin / Q000493:pharmacokinetics
chemical_list: D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D004338:Drug Combinations; D015377:Cilastatin; D014640:Vancomycin; D015378:Imipenem; D000077728:Cilastatin, Imipenem Drug Combination